An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of extended dosing of
IONIS-PKK-LRx administered subcutaneously (SC), with alternative dosing and/or dose frequency
with IONIS-PKK-LRx in participants with hereditary angioedema (HAE).